Arvinas, Inc. (ARVN) Cash Flow Statement

The extreme volatility in the OCF/NI ratio indicates that net income is heavily influenced by non-cash accounting adjustments and the timing of milestone revenue recognition. Investors should interpret these figures with caution, as the lack of a consistent conversion ratio highlights the difficulty in assessing core operational health through traditional earnings metrics.

The trajectory of free cash flow remains firmly in negative territory, reflecting the heavy R&D burden inherent in late-stage biotech development. This persistent burn rate suggests that the company's long-term viability is contingent upon either achieving commercial milestones or securing additional dilutive financing to bridge the gap to profitability.

The erratic nature of working capital movements appears to be a direct consequence of the milestone-driven revenue model, where large cash inflows are often preceded by significant operational outlays. This dynamic warrants further investigation, as it complicates the predictability of cash runway and forces management to maintain higher liquidity buffers than would otherwise be necessary.

The decision to allocate capital toward share buybacks while simultaneously burning cash to fund R&D may indicate management's attempt to support the stock price during periods of clinical uncertainty. Investors should monitor whether this deployment strategy remains sustainable if the company's cash runway continues to tighten in the coming quarters.